UdKag 150

UdKag 150 mg Tablets — Eskag Pharma

UdKag (Ursodeoxycholic Acid, UDCA) supports dissolution of radiolucent cholesterol gallstones and management of cholestatic liver disorders such as primary biliary cholangitis (PBC). UDCA lowers biliary cholesterol saturation, enhances bile flow, and protects hepatocytes.

Key Features

• IP-grade UDCA 150 mg for flexible, weight-based dosing
• Uncoated tablet for dependable disintegration and absorption
• 10×10 pack optimized for clinics and hospital use
• Consistent quality from Eskag Pharma

Indications

• Dissolution of radiolucent (non-calcified) cholesterol gallstones with a functioning gallbladder
• Primary biliary cholangitis (PBC)
• Adjunct in other cholestatic liver diseases as directed by a physician
• Biliary reflux gastritis (as clinically appropriate)

Dosage & Administration*

• Gallstone dissolution: ~8–10 mg/kg/day in 1–2 divided doses after meals
• PBC / cholestatic disorders: 13–15 mg/kg/day in 2–3 divided doses after meals
• Swallow with water, preferably after food; duration per clinical response.
  *General guidance; individualize as per physician’s judgement.

Mechanism of Action

Replaces hydrophobic bile acids, reduces intestinal and biliary cholesterol, decreases bile cholesterol saturation, and promotes choleresis—helping protect cholangiocytes and hepatocytes.

Contraindications

• Hypersensitivity to UDCA or any excipient
• Calcified/radiopaque stones, non-functioning gallbladder
• Acute cholecystitis, complete biliary obstruction, acute cholangitis, biliary-enteric fistula
• Use in pregnancy/lactation only if clearly needed and prescribed

Warnings & Precautions

• Monitor liver function periodically
• Confirm stone type and gallbladder function before initiation
• Discontinue if persistent transaminase elevation or intolerable GI symptoms

Adverse Effects

Generally, well tolerated. Possible: diarrhea, nausea, abdominal pain, pruritus, rash; rarely elevated transaminases or stone calcification.

Drug Interactions

• Bile acid sequestrants, aluminum antacids, activated charcoal may reduce absorption—separate by ≥2 hours.
• Ciprofloxacin, cyclosporine, estrogenic contraceptives, lipid-lowering agents: monitor as they may alter bile composition or UDCA levels.

Storage

Store below 25°C, protected from light and moisture. Keep out of reach of children.

Packaging

Blister/Alu-Alu* packs of 10×10 tablets (100 tablets per mono-carton).
*Specify exact pack material per final specification.

Regulatory (India)

Schedule H prescription drug. To be sold by retail on the prescription of a Registered Medical Practitioner only.